Trientine-Dihydrochloride shortage — AU supply status & alternatives

Trientine-Dihydrochloride

—

In shortage · Australia

TRIENTINE DR.REDDYS trientine dihydrochloride

In declared shortage · 🇦🇺 Australia & also short in🇫🇷 FR🇬🇷 GR

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Trientine-Dihydrochloride

Brand names	TRIENTINE DR.REDDYS trientine dihydrochloride

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 5h ago

High

🇫🇷

France

ANSM · 5h ago

Medium

🇬🇷

EOF · 22h ago

Medium

Verified timeline regulator events

🇬🇷 2 Mar 2026

medium reported

🇦🇺 23 Jan 2026

high reported

🇫🇷 28 Nov 2025

medium reported

Sources official regulators

🇦🇺

TGA

verified 5h ago

verify ↗

🇫🇷

ANSM

verified 5h ago

verify ↗

🇬🇷

EOF

verified 22h ago

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 3 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.